RNXT RenovoRx (RNXT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001574094
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter
What the filings say about RNXT
Insiders, 180 days
+$19.8K net bought
1 buyer
RenovoRx insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, RenovoRx, Inc. insiders bought a net $19.8K of stock across 36 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 17.6% of the 142,380 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer VOLL MARK bought about $19.8K of RNXT on May 19, 2026; 12 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Dec 31, 2025.
- +19.3% median (+28.2% mean) 90-day return after 12 previous buys.
- The trade is 1.3% of the 798,460 shares held after it.
- No other insider bought within 30 days.
- 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Agah Ramtin bought about $10.0K of RNXT on Jan 21, 2026; 12 funds added in the latest 13F quarter.36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$19.8K over 180 days
more than 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 79% of Pharma & Biotech
Revenue
+2511.6% year over year
more than 97% of Pharma & Biotech
Margin
-994.5% net margin
below 85% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.2% of the float short (float per yahoo 2026-10-27) · 1.6 days to cover · settled 2026-10-15
below 66% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RNXT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RNXT: institutional holders (13F)
13F holdings, latest reported quarter
4,405,439 sh
$4.3M
1,666,098 sh
$1.6M
1,443,742 sh
$1.4M
424,148 sh
$415.7K
252,525 sh
$247.5K
Congress trades in RNXT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RNXT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
RNXT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$372.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$162.2K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$18.6K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$70.9K position · as of 2026-05-31
0.0%
VANGUARD BALANCED INDEX FUND
$29.0K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$1.0M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
1 active
1
Not applicable
1 active
What changed recently
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy
2026-10-01 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $19.8K bought by insiders over 180 days, 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
RNXT financials
Revenue growth
+2511.6%
XBRL, annual
Net margin
-994.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RNXT
| FY Dec 2025 | $1.1M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $909.0K |
| Mar 2026 | $563.0K |
| Dec 2025 | $238.0K |
| Sep 2025 | $266.0K |
| Jun 2025 | $422.0K |
| Mar 2025 | $197.0K |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
-621.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RNXT
| FY Dec 2025 | -994.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -320.2% |
| Mar 2026 | -625.4% |
| Dec 2025 | n/a |
| Sep 2025 | -1,095% |
| Jun 2025 | -686.0% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$11.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RNXT
| FY Dec 2025 | -$11.0M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$2.9M |
| Mar 2026 | -$3.7M |
| Dec 2025 | -$3.0M |
| Sep 2025 | -$2.3M |
| Jun 2025 | -$2.3M |
| Mar 2025 | -$3.4M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity RNXT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt RNXT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-125.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RNXT
| FY Dec 2025 | -225.6% |
| FY Dec 2024 | -235.7% |
| FY Dec 2023 | -223.3% |
| FY Dec 2022 | -91.9% |
| FY Dec 2021 | -1,825% |
| Jun 2026 | -125.2% |
| Mar 2026 | -100.5% |
| Dec 2025 | -225.6% |
| Sep 2025 | -146.6% |
| Jun 2025 | -107.1% |
| Mar 2025 | -136.1% |
| Dec 2024 | -235.7% |
| Sep 2024 | -259.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-97.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RNXT
| FY Dec 2025 | -137.8% |
| FY Dec 2024 | -183.9% |
| FY Dec 2023 | -234.4% |
| FY Dec 2022 | -84.0% |
| FY Dec 2021 | -69.5% |
| Jun 2026 | -97.8% |
| Mar 2026 | -81.9% |
| Dec 2025 | -137.8% |
| Sep 2025 | -104.6% |
| Jun 2025 | -83.2% |
| Mar 2025 | -97.7% |
| Dec 2024 | -183.9% |
| Sep 2024 | -135.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital RNXT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-124.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RNXT
| FY Dec 2025 | -202.7% |
| FY Dec 2024 | -337.5% |
| FY Dec 2023 | -353.1% |
| FY Dec 2022 | -92.5% |
| FY Dec 2021 | -86.1% |
| Jun 2026 | -124.9% |
| Mar 2026 | -97.8% |
| Dec 2025 | -202.7% |
| Sep 2025 | -132.2% |
| Jun 2025 | -98.8% |
| Mar 2025 | -129.1% |
| Dec 2024 | -337.5% |
| Sep 2024 | -198.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RNXT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value RNXT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-20.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield RNXT
| FY Dec 2025 | -35.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -27.0% |
| Mar 2026 | -24.8% |
| Dec 2025 | -35.6% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RNXT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.1M | $43.0K | n/a | n/a |
| Gross profit | $796.0K | $43.0K | n/a | n/a |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M |
| EPS (diluted) | -0.32 | -0.40 | -0.99 | -1.09 |
| Operating cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M |
| Cash | $7.0M | $7.2M | $1.2M | $4.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
RNXT Stock Sonar score 5/7 axes
Find similar shapesCompareRNXT ranks highest on growth (97th percentile) and risk and compliance (73rd), and lowest on institutional and government (21st), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RNXT filings, in plain words
Are RenovoRx insiders buying or selling RNXT?
In the 180 days to 2026-10-28, RenovoRx insiders were net buyers, a net $19.8K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, RenovoRx insiders were net buyers of RNXT, a net $19.8K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
